You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGlipizide
Accession NumberDB01067  (APRD00436)
TypeSmall Molecule
GroupsApproved
DescriptionAn oral hypoglycemic agent which is rapidly absorbed and completely metabolized. [PubChem]
Structure
Thumb
Synonyms
1-Cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea
Aldiab
CP 28,720
CP 28720
CP-28,720
Digrin
Dipazide
Glibenese
Glibetin
Glican
Glidiab
Glipid
Glipizida
Glipizidum
Gluco-rite
Glucolip
Glucotrol
Glucozide
Glupitel
Glupizide
Glyde
Glydiazinamide
K 4024
Melizide
Mindiab
Minidab
Minidiab
Minodiab
N-{4-[beta-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-n'-cyclohexylurea
Napizide
Ozidia
Sucrazide
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GlipizideTablet, extended release5 mg/1OralRemedy Repack2011-12-082016-12-14Us
Glipizide ERTablet, extended release10 mg/1OralCardinal Health1994-04-26Not applicableUs
Glipizide XLTablet, extended release5 mg/1OralSt. Marys Medical Park Pharmacy2014-05-23Not applicableUs
Glipizide XLTablet, extended release10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Glipizide XLTablet, extended release2.5 mg/1OralGreenstone, Llc2013-05-29Not applicableUs
Glipizide XLTablet, extended release5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Glipizide XLTablet, extended release5 mg/1OralGreenstone, Llc2013-05-29Not applicableUs
Glipizide XLTablet, extended release10 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Glipizide XLTablet, extended release2.5 mg/1OralCardinal Health1994-04-26Not applicableUs
Glipizide XLTablet, extended release10 mg/1OralGreenstone, Llc2013-05-29Not applicableUs
Glipizide XLTablet, extended release2.5 mg/1OralCardinal Health1994-04-26Not applicableUs
Glipizide XLTablet, extended release5 mg/1OralGreenstone, Llc2004-06-112017-03-31Us
Glipizide XLTablet, extended release10 mg/1OralGreenstone, Llc2004-06-11Not applicableUs
GlucotrolTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.1984-05-08Not applicableUs
GlucotrolTablet5 mg/1OralRoerig1984-05-08Not applicableUs
GlucotrolTablet10 mg/1OralRoerig1984-05-08Not applicableUs
Glucotrol XLTablet, extended release2.5 mg/1OralRoerig2013-07-15Not applicableUs
Glucotrol XLTablet, extended release5 mg/1OralRoerig2013-10-01Not applicableUs
Glucotrol XLTablet, extended release10 mg/1OralRoerig2013-05-09Not applicableUs
Glucotrol XLTablet, extended release5 mg/1OralRoerig1994-04-262016-11-30Us
Glucotrol XLTablet, extended release10 mg/1OralPhysicians Total Care, Inc.1994-09-30Not applicableUs
Glucotrol XLTablet, extended release10 mg/1OralRoerig1999-04-10Not applicableUs
Glucotrol XLTablet, extended release5 mg/1OralPhysicians Total Care, Inc.1994-08-01Not applicableUs
Glucotrol XLTablet, extended release2.5 mg/1OralPhysicians Total Care, Inc.2003-05-08Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GlipizideTablet10 mg/1OralLegacy Pharmaceutical Packaging1995-04-07Not applicableUs
GlipizideTablet, extended release5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-09-08Not applicableUs
GlipizideTablet10 mg/1OralApotex Corporation2002-09-25Not applicableUs
GlipizideTablet5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
GlipizideTablet10 mg/1OralCardinal Health2010-11-04Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2017-03-23Not applicableUs
GlipizideTablet5 mg/1OralAphena Pharma Solutions Tennessee, Inc.1995-04-07Not applicableUs
GlipizideTablet10 mg/1OralNucare Pharmaceuticals, Inc.2002-09-25Not applicableUs
GlipizideTablet10 mg/1OralLake Erie Medical Dba Quality Care Produts Llc1995-04-07Not applicableUs
GlipizideTablet5 mg/1OralMylan Institutional1994-07-12Not applicableUs
GlipizideTablet10 mg/1OralRemedy Repack2011-09-262016-11-11Us
GlipizideTablet5 mg/1OralPreferreed Pharmaceuticals Inc.2013-02-18Not applicableUs
GlipizideTablet, film coated, extended release5 mg/1OralPhysicians Total Care, Inc.2005-01-18Not applicableUs
GlipizideTablet10 mg/1OralMc Kesson Contract Packaging2011-11-22Not applicableUs
GlipizideTablet5 mg/1OralUnit Dose Services1995-02-27Not applicableUs
GlipizideTablet10 mg/1OralClinical Solutions Wholsesale1995-02-27Not applicableUs
GlipizideTablet10 mg/1OralDirectrx2017-02-20Not applicableUs
GlipizideTablet10 mg/1OralRemedy Repack2013-10-032016-12-28Us
GlipizideTablet10 mg/1OralGolden State Medical Supply2012-09-20Not applicableUs
GlipizideTablet10 mg/1OralStat Rx USA1995-02-27Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2013-05-302017-12-30Us
GlipizideTablet5 mg/1OralProficient Rx LP1995-04-07Not applicableUs
GlipizideTablet10 mg/1OralA S Medication Solutions2002-09-25Not applicableUs
GlipizideTablet, extended release2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-09-08Not applicableUs
GlipizideTablet5 mg/1OralActavis Pharma Company1995-02-27Not applicableUs
GlipizideTablet5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
GlipizideTablet5 mg/1OralMajor2002-09-25Not applicableUs
GlipizideTablet5 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
GlipizideTablet, film coated, extended release10 mg/1OralRemedy Repack2017-04-04Not applicableUs
GlipizideTablet5 mg/1OralTYA Pharmaceuticals2011-03-01Not applicableUs
GlipizideTablet10 mg/1OralNorthwind Pharmaceuticals2015-09-30Not applicableUs
GlipizideTablet5 mg/1OralNucare Pharmaceuticals, Inc.2011-07-18Not applicableUs
GlipizideTablet10 mg/1OralMylan Institutional1994-07-12Not applicableUs
GlipizideTablet10 mg/1OralRemedy Repack2011-05-112016-11-18Us
GlipizideTablet10 mg/1OralPreferreed Pharmaceuticals Inc.2013-02-18Not applicableUs
GlipizideTablet, film coated, extended release2.5 mg/1OralPhysicians Total Care, Inc.2005-07-25Not applicableUs
GlipizideTablet5 mg/1OralSun Pharmaceutical Industries Limited2009-07-31Not applicableUs
GlipizideTablet5 mg/1OralIVAX Pharmaceuticals, Inc.1995-09-122015-10-31Us
GlipizideTablet10 mg/1OralRemedy Repack2016-11-08Not applicableUs
GlipizideTablet, film coated, extended release2.5 mg/1OralMylan Pharmaceuticals2015-05-19Not applicableUs
GlipizideTablet10 mg/1OralRemedy Repack2016-12-01Not applicableUs
GlipizideTablet5 mg/1OralNorthwind Pharmaceuticals2014-12-29Not applicableUs
GlipizideTablet10 mg/1OralNucare Pharmaceuticals, Inc.2011-07-18Not applicableUs
GlipizideTablet10 mg/1OralBlenheim Pharmacal, Inc.2010-09-09Not applicableUs
GlipizideTablet10 mg/1OralMylan Pharmaceuticals1994-05-10Not applicableUs
GlipizideTablet10 mg/1OralSt. Marys Medical Park Pharmacy2013-05-09Not applicableUs
GlipizideTablet5 mg/1OralRebel Distributors1995-02-27Not applicableUs
GlipizideTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-09-25Not applicableUs
GlipizideTablet10 mg/1OralProficient Rx LP2011-03-01Not applicableUs
GlipizideTablet, film coated, extended release5 mg/1OralPar Pharmaceutical2016-12-21Not applicableUs
GlipizideTablet10 mg/1OralActavis Pharma Company1995-02-27Not applicableUs
GlipizideTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
GlipizideTablet, film coated, extended release10 mg/1OralA S Medication Solutions2016-12-21Not applicableUs
GlipizideTablet10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
GlipizideTablet5 mg/1OralRed Pharm Drug, Inc.1995-04-07Not applicableUs
GlipizideTablet10 mg/1OralMed Vantx, Inc.2012-03-18Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2010-11-232017-03-03Us
GlipizideTablet5 mg/1Oralbryant ranch prepack1995-02-27Not applicableUs
GlipizideTablet, film coated, extended release5 mg/1OralPar Pharmaceutical2013-09-23Not applicableUs
GlipizideTablet10 mg/1OralPreferreed Pharmaceuticals Inc.2011-04-25Not applicableUs
GlipizideTablet10 mg/1OralSun Pharmaceutical Industries Limited2009-07-31Not applicableUs
GlipizideTablet10 mg/1OralIVAX Pharmaceuticals, Inc.1995-08-312015-11-30Us
GlipizideTablet5 mg/1OralSandoz1995-04-07Not applicableUs
GlipizideTablet, film coated, extended release5 mg/1OralMylan Pharmaceuticals2015-05-19Not applicableUs
GlipizideTablet10 mg/1OralNorthwind Pharmaceuticals2014-12-30Not applicableUs
GlipizideTablet5 mg/1OralDirectrx2014-01-01Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2014-06-162016-12-14Us
GlipizideTablet5 mg/1OralAccord Healthcare Limited2011-03-01Not applicableUs
GlipizideTablet5 mg/1OralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
GlipizideTablet10 mg/1OralRemedy Repack2011-06-272016-10-28Us
GlipizideTablet5 mg/1OralSt. Marys Medical Park Pharmacy2013-05-09Not applicableUs
GlipizideTablet10 mg/1OralRebel Distributors1995-02-27Not applicableUs
GlipizideTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-09-25Not applicableUs
GlipizideTablet5 mg/1OralProficient Rx LP2011-03-01Not applicableUs
GlipizideTablet10 mg/1OralPreferreed Pharmaceuticals Inc.2016-12-13Not applicableUs
GlipizideTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1994-05-10Not applicableUs
GlipizideTablet, film coated, extended release10 mg/1OralPar Pharmaceutical2016-12-21Not applicableUs
GlipizideTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
GlipizideTablet5 mg/1OralPhysicians Total Care, Inc.1994-07-26Not applicableUs
GlipizideTablet, film coated, extended release5 mg/1OralA S Medication Solutions2013-09-23Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2016-05-042017-02-22Us
GlipizideTablet10 mg/1OralAidarex Pharmaceuticals LLC2002-09-25Not applicableUs
GlipizideTablet10 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-03-01Not applicableUs
GlipizideTablet10 mg/1OralRemedy Repack2011-04-182016-10-13Us
GlipizideTablet5 mg/1OralClinical Solutions Wholsesale1995-04-07Not applicableUs
GlipizideTablet10 mg/1OralClinical Solutions Wholsesale1995-04-07Not applicableUs
GlipizideTablet10 mg/1OralA S Medication Solutions2011-07-18Not applicableUs
GlipizideTablet10 mg/1OralSandoz1995-04-07Not applicableUs
GlipizideTablet, film coated, extended release10 mg/1OralMylan Pharmaceuticals2015-05-19Not applicableUs
GlipizideTablet, film coated, extended release10 mg/1OralPar Pharmaceutical2013-09-23Not applicableUs
GlipizideTablet5 mg/1OralPreferreed Pharmaceuticals Inc.2012-01-30Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2013-01-032017-02-22Us
GlipizideTablet5 mg/1OralDirectrx2017-02-24Not applicableUs
GlipizideTablet5 mg/1OralBlenheim Pharmacal, Inc.2013-09-30Not applicableUs
GlipizideTablet10 mg/1OralUnit Dose Services1995-02-27Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2014-09-052017-02-02Us
GlipizideTablet5 mg/1OralA S Medication Solutions2002-09-25Not applicableUs
GlipizideTablet5 mg/1OralPreferreed Pharmaceuticals Inc.2016-12-13Not applicableUs
GlipizideTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1994-05-10Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2017-01-11Not applicableUs
GlipizideTablet10 mg/1OralRemedy Repack2014-06-162016-12-14Us
GlipizideTablet10 mg/1OralAccord Healthcare Limited2011-03-01Not applicableUs
GlipizideTablet5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
GlipizideTablet, film coated, extended release10 mg/1OralA S Medication Solutions2013-09-23Not applicableUs
GlipizideTablet5 mg/1OralContract Pharmacy Services Pa2010-04-05Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2016-06-07Not applicableUs
GlipizideTablet5 mg/1OralApotheca, Inc.2011-07-18Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2011-04-282016-10-15Us
GlipizideTablet10 mg/1OralClinical Solutions Wholsesale1995-04-07Not applicableUs
GlipizideTablet10 mg/1OralPhysicians Total Care, Inc.1994-11-18Not applicableUs
GlipizideTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.1995-02-27Not applicableUs
GlipizideTablet5 mg/1OralA S Medication Solutions2011-07-18Not applicableUs
GlipizideTablet5 mg/1OralA S Medication Solutions2011-07-18Not applicableUs
GlipizideTablet5 mg/1OralUpsher Smith Laboratories2015-03-092017-07-31Us
GlipizideTablet5 mg/1OralMylan Pharmaceuticals1994-05-10Not applicableUs
GlipizideTablet10 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-05-31Not applicableUs
GlipizideTablet10 mg/1OralProficient Rx LP1995-02-27Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2013-01-022017-01-27Us
GlipizideTablet10 mg/1OralAidarex Pharmaceuticals LLC2011-07-18Not applicableUs
GlipizideTablet5 mg/1OralClinical Solutions Wholsesale1995-04-07Not applicableUs
GlipizideTablet10 mg/1OralBlenheim Pharmacal, Inc.2013-09-30Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2012-07-19Not applicableUs
GlipizideTablet10 mg/1OralRemedy Repack2014-10-032017-02-04Us
GlipizideTablet10 mg/1OralA S Medication Solutions1995-02-27Not applicableUs
GlipizideTablet5 mg/1OralLegacy Pharmaceutical Packaging1995-04-07Not applicableUs
GlipizideTablet, extended release10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-09-08Not applicableUs
GlipizideTablet5 mg/1OralApotex Corporation2002-09-25Not applicableUs
GlipizideTablet10 mg/1OralH.J. Harkins Company1995-02-27Not applicableUs
GlipizideTablet5 mg/1OralCardinal Health2010-11-04Not applicableUs
GlipizideTablet5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
GlipizideTablet5 mg/1OralAvera Mc Kennan Hospital2016-05-16Not applicableUs
GlipizideTablet10 mg/1OralAphena Pharma Solutions Tennessee, Inc.1995-04-07Not applicableUs
GlipizideTablet10 mg/1OralApotheca, Inc.2011-07-18Not applicableUs
GlipizideTablet, film coated, extended release5 mg/1OralRemedy Repack2011-06-012017-03-16Us
GlipizideTablet10 mg/1Oralbryant ranch prepack1995-02-27Not applicableUs
GlipizideTablet, film coated, extended release10 mg/1OralPhysicians Total Care, Inc.2004-01-30Not applicableUs
GlipizideTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.1995-04-07Not applicableUs
GlipizideTablet5 mg/1OralMc Kesson Contract Packaging2011-10-03Not applicableUs
GlipizideTablet10 mg/1OralA S Medication Solutions2011-07-18Not applicableUs
GlipizideTablet10 mg/1OralUpsher Smith Laboratories2015-03-092017-07-31Us
GlipizideTablet5 mg/1OralLake Erie Medical Dba Quality Care Produts Llc1995-04-07Not applicableUs
GlipizideTablet10 mg/1Oralbryant ranch prepack1995-02-27Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2013-03-012016-10-13Us
GlipizideTablet, film coated, extended release10 mg/1OralNu Care Pharmaceuticals Inc,2016-12-21Not applicableUs
GlipizideTablet5 mg/1OralGolden State Medical Supply2012-09-20Not applicableUs
GlipizideTablet5 mg/1OralStat Rx USA1995-02-27Not applicableUs
GlipizideTablet10 mg/1OralRemedy Repack2013-05-222017-09-14Us
GlipizideTablet5 mg/1OralAidarex Pharmaceuticals LLC2002-09-25Not applicableUs
GlipizideTablet10 mg/1OralA S Medication Solutions1995-04-07Not applicableUs
Glipizide ERTablet, film coated, extended release5 mg/1OralWatson Pharmaceuticals2003-11-01Not applicableUs
Glipizide ERTablet, extended release10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Glipizide ERTablet, film coated, extended release2.5 mg/1Oralbryant ranch prepack2006-04-01Not applicableUs
Glipizide ERTablet, film coated, extended release2.5 mg/1OralUnit Dose Services2006-04-01Not applicableUs
Glipizide ERTablet, film coated, extended release5 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2003-11-01Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralA S Medication Solutions2015-07-02Not applicableUs
Glipizide ERTablet, film coated, extended release5 mg/1OralUnit Dose Services2003-11-01Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralRemedy Repack2017-03-07Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralPar Pharmaceutical2015-07-02Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralWatson Pharmaceuticals2003-11-07Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralNucare Pharmaceuticals, Inc.2015-07-02Not applicableUs
Glipizide ERTablet, film coated, extended release5 mg/1OralAmerincan Health Packaging2008-06-09Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2003-11-07Not applicableUs
Glipizide ERTablet, film coated, extended release5 mg/1OralNucare Pharmaceuticals, Inc.2015-07-02Not applicableUs
Glipizide ERTablet, film coated, extended release2.5 mg/1OralWatson Pharmaceuticals2006-04-01Not applicableUs
Glipizide ERTablet, film coated, extended release5 mg/1OralPar Pharmaceutical2015-07-02Not applicableUs
Glipizide ERTablet, film coated, extended release5 mg/1OralA S Medication Solutions2003-11-01Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralA S Medication Solutions2015-07-02Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralAmerincan Health Packaging2008-06-09Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralPd Rx Pharmaceuticals, Inc.2003-11-07Not applicableUs
Glipizide ERTablet, film coated, extended release2.5 mg/1OralUnit Dose Services2006-04-01Not applicableUs
Glipizide ERTablet, extended release2.5 mg/1OralActavis Elizabeth LLC2003-09-08Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralAvera Mc Kennan Hospital2016-02-15Not applicableUs
Glipizide ERTablet, film coated, extended release5 mg/1OralRemedy Repack2017-04-24Not applicableUs
Glipizide ERTablet, film coated, extended release5 mg/1OralDispensing Solutions, Inc.2003-11-01Not applicableUs
Glipizide ERTablet, film coated, extended release2.5 mg/1OralAmerincan Health Packaging2008-10-30Not applicableUs
Glipizide ERTablet, film coated, extended release2.5 mg/1OralAvera Mc Kennan Hospital2015-11-02Not applicableUs
Glipizide ERTablet, film coated, extended release2.5 mg/1OralRebel Distributors2006-04-01Not applicableUs
Glipizide ERTablet, extended release5 mg/1OralActavis Elizabeth LLC2003-09-08Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralAvera Mc Kennan Hospital2016-03-15Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralCarilion Materials Management2003-11-07Not applicableUs
Glipizide ERTablet, extended release10 mg/1OralActavis Elizabeth LLC2003-09-08Not applicableUs
Glipizide ERTablet, film coated, extended release5 mg/1Oralbryant ranch prepack2003-11-01Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralA S Medication Solutions2003-11-07Not applicableUs
Glipizide ERTablet, film coated, extended release5 mg/1OralRemedy Repack2016-08-18Not applicableUs
Glipizide ERTablet, film coated, extended release5 mg/1OralA S Medication Solutions2015-07-02Not applicableUs
Glipizide ERTablet, film coated, extended release10 mg/1OralDirectrx2015-01-01Not applicableUs
GlipizideerTablet, film coated, extended release10 mg/1Oralbryant ranch prepack2003-11-07Not applicableUs
Glipizideer ERTablet, film coated, extended release2.5 mg/1OralRemedy Repack2013-11-122017-02-25Us
Glipizideer ERTablet, film coated, extended release5 mg/1OralPd Rx Pharmaceuticals, Inc.2003-11-01Not applicableUs
Glipizideer ERTablet, film coated, extended release5 mg/1OralAidarex Pharmaceuticals LLC2003-11-01Not applicableUs
Glipizideer ERTablet, film coated, extended release10 mg/1OralRemedy Repack2013-11-122016-11-08Us
Glipizideer ERTablet, film coated, extended release10 mg/1OralAidarex Pharmaceuticals LLC2003-11-07Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
GlibenesePfizer
GlibénèseDexo
GlibetinJohnson
GlipinSwiss Pharm
GlixYSP
MindiabPfizer
MinidiabPfizer
Zitrol XRSquare
Brand mixtures
NameLabellerIngredients
Glipizide and Metformin HClLake Erie Medical Dba Quality Care Produts Llc
Glipizide and Metformin HydrochlorideWatson Pharmaceuticals
Categories
UNIIX7WDT95N5C
CAS number29094-61-9
WeightAverage: 445.535
Monoisotopic: 445.178375067
Chemical FormulaC21H27N5O4S
InChI KeyZJJXGWJIGJFDTL-UHFFFAOYSA-N
InChI
InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)
IUPAC Name
N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide
SMILES
CC1=CN=C(C=N1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
Pharmacology
IndicationFor use as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory.
Structured Indications
PharmacodynamicsGlipizide, a second-generation sulfonylurea, is used with diet to lower blood glucose in patients with diabetes mellitus type II. The primary mode of action of glipizide in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pancreatic islets. In humans glipizide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. In man, stimulation of insulin secretion by glipizide in response to a meal is undoubtedly of major importance. Fasting insulin levels are not elevated even on long-term glipizide administration, but the postprandial insulin response continues to be enhanced after at least 6 months of treatment. Some patients fail to respond initially, or gradually lose their responsiveness to sulfonylurea drugs, including glipizide.
Mechanism of actionSulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.
TargetKindPharmacological actionActionsOrganismUniProt ID
ATP-binding cassette sub-family C member 8Proteinyes
inhibitor
HumanQ09428 details
Peroxisome proliferator-activated receptor gammaProteinunknown
agonist
HumanP37231 details
Related Articles
AbsorptionGastrointestinal absorption is uniform, rapid, and essentially complete.
Volume of distribution
  • 11 L
Protein binding98-99%, primarily to albumin.
Metabolism

Hepatic. The major metabolites of glipizide are products of aromatic hydroxylation and have no hypoglycemic activity. A minor metabolite which accounts for less than 2% of a dose, an acetylaminoethyl benzine derivatives, is reported to have 1/10 to 1/3 as much hypoglycemic activity as the parent compound.

SubstrateEnzymesProduct
Glipizide
Not Available
3-cis-HydroxyglipizideDetails
Glipizide
4-trans-HydroxyglipizideDetails
Route of eliminationThe primary metabolites are inactive hydroxylation products and polar conjugates and are excreted mainly in the urine.
Half life2-5 hours
ClearanceNot Available
ToxicityThe acute oral toxicity was extremely low in all species tested (LD50 greater than 4 g/kg). Overdosage of sulfonylureas including glipizide can produce hypoglycemia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeSNP RS IDsAllele nameGenotypeDefining ChangeType(s)DescriptionDetails
Cytochrome P450 2C9CYP2C9*3(C;C) or (A;C)C AlleleEffect Directly StudiedPoor drug metabolizer, lower dose requirements Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableVilleurbanne---1000_1002delACCADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableTorun---1006A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSunderland---105_107delCATADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableIwatsuki---1081G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSerres---1082C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableTondela---1084_1101delCTGAACGAGCGCAAGGCCADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableLoma Linda---1089C->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAachen---1089C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableTenri---1096A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMontpellier---1132G>AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableCalvo Mackenna---1138A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableRiley---1139T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableOlomouc---1141T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableTomah---1153T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableLynwood---1154G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMadrid---1155C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableIowa, Walter Reed, Springfield---1156A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableBeverly Hills, Genova, Iwate, Niigata, Yamaguchi---1160G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableHartford---1162A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailablePraha---1166A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableKrakow---1175T>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableWisconsin---1177C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableNashville, Anaheim, Portici---1178G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAlhambra---1180G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableBari---1187C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailablePuerto Limon---1192G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableCovao do Lobo---1205C>AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableClinic---1215G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableUtrecht---1225C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSuwalki---1226C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableRiverside---1228G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableJapan, Shinagawa---1229G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableKawasaki---1229G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMunich---1231A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableGeorgia---1284C->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSumare---1292T->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableTelti/Kobe---1318C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSantiago de Cuba, Morioka---1339G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableHarima---1358T->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableFiguera da Foz---1366G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAmiens---1367A>TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableBangkok Noi---1376G->T, 1502T->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableFukaya---1462G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableCampinas---1463G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableBuenos Aires---1465C>TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableArakawa---1466C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableBrighton---1488_1490delGAAADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableKozukata---159G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAmsterdam---180_182delTCTADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableNo name---202G->A, 376A->G, 1264C>GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSwansea---224T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableUrayasu---281_283delAGAADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableVancouver---317C->G544C->T592C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMt Sinai---376A->G, 1159C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailablePlymouth---488G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableVolendam---514C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableShinshu---527A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableChikugo---535A->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableTsukui---561_563delCTCADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailablePedoplis-Ckaro---573C>GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSantiago---593G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMinnesota, Marion, Gastonia, LeJeune---637G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableCincinnati---637G->T, 1037A->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableHarilaou---648T->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableNorth Dallas---683_685delACAADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAsahikawa---695G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableDurham---713A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableStonybrook---724_729delGGCACTADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableWayne---769C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAveiro---806G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableCleveland Corum---820G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableLille---821A>TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableBangkok---825G>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSugao---826C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableLa Jolla---832T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableWexham---833C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailablePiotrkow---851T>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableWest Virginia---910G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableOmiya---921G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableNara---953_976delCCACCAAAGGGTACCTGGAC GACCADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableManhattan---962G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableRehevot---964T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableHoniara---99A->G, 1360C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableTokyo, Fukushima---1246G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableChatham---1003G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableFushan---1004C->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailablePartenope---1052G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableIerapetra---1057C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAnadia---1193A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAbeno---1220A->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSurabaya---1291G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailablePawnee---1316G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableS. Antioco---1342A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableCassano---1347G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableHermoupolis---1347G->C, 1360C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableUnion,Maewo, Chinese-2, Kalo---1360C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAndalus---1361G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableCosenza---1376G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableCanton, Taiwan- Hakka, Gifu-like, Agrigento-like---1376G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableFlores---1387C->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableKaiping, Anant, Dhon, Sapporo-like, Wosera---1388G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableKamogawa---169C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableCostanzo---179T>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAmazonia---185C->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSongklanagarind---196T->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableHechi---202G->A, 871G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableNamouru---208T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableBao Loc---352T>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableCrispim---375G->T, 379G->T383T->C384C>TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAcrokorinthos---376A->G, 463C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSanta Maria---376A->G, 542A->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAnanindeua---376A->G, 871G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableVanua Lava---383T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableValladolid---406C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableBelem---409C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableLiuzhou---442G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableShenzen---473G>AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableTaipei “Chinese- 3”---493A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableToledo---496C>TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableNaone---497G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableNankang---517T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMiaoli---519C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMediterranean, Dallas, Panama‚ Sassari, Cagliari, Birmingham---563C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableCoimbra Shunde---592C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableNilgiri---593G>AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableRadlowo---679C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableRoubaix---811G>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableHaikou---835A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableChinese-1---835A->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMizushima---848A>GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableOsaka---853C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableViangchan, Jammu---871G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSeoul---916G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableLudhiana---929G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableFarroupilha---977C->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableChinese-5---1024C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableRignano---130G>AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableOrissa---131C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableG6PDNice---1380G>CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableKamiube, Keelung---1387C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableNeapolis---1400C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAures---143T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSplit---1442C->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableKambos---148C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailablePalestrina---170G>AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMetaponto---172G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMusashino---185C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableAsahi---202G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableA- (202), Ferrara I---202G->A, 376A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMurcia Oristano---209A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableUbe Konan---241C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableLagosanto---242G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableGuangzhou---274C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableHammersmith---323T->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSinnai---34G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableA- (680)---376A->G, 680G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableA- (968), Betica,Selma, Guantanamo---376A->G, 968T->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSalerno Pyrgos---383T>GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableQuing Yan---392G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableLages---40G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableIlesha---466G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMahidol---487G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMalaga---542A->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSibari---634A->GADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMexico City---680G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableNanning---703C->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableSeattle, Lodi, Modena, Ferrara II, Athens-like---844G->CADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableBajo Maumere---844G->TADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableMontalbano---854G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableKalyan-Kerala, Jamnaga, Rohini---949G->AADR InferredIncreased risk of hemolytic anemia. Details
Glucose-6-phosphate 1-dehydrogenaseNot AvailableGaohe---95A->GADR InferredIncreased risk of hemolytic anemia. Details
Cytochrome P450 2C9CYP2C9*6---818delAEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*15---485C>AEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*25---353_362delAGAAATGGAAEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9Not AvailableCYP2C9*35---374G>T / 430C>TEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*2---430C>TEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*3---1075A>CEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*4---1076T>CEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*5---1080C>GEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*8---449G>AEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*11---1003C>TEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*12---1465C>TEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*13---269T>CEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*14---374G>AEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*16---895A>GEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9Not AvailableCYP2C9*18---1075A>C / 1190A>C  … show all Effect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9Not AvailableCYP2C9*26---389C>GEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9Not AvailableCYP2C9*28---641A>TEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9Not AvailableCYP2C9*30---1429G>AEffect InferredPoor drug metabolizer, lower dose requirements Details
Cytochrome P450 2C9CYP2C9*33---395G>AEffect InferredPoor drug metabolizer, lower dose requirements Details
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Glipizide.Experimental
AbirateroneThe metabolism of Glipizide can be decreased when combined with Abiraterone.Approved
AcarboseAcarbose may increase the hypoglycemic activities of Glipizide.Approved, Investigational
AcebutololAcebutolol may increase the hypoglycemic activities of Glipizide.Approved
AcenocoumarolGlipizide may increase the anticoagulant activities of Acenocoumarol.Approved
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Glipizide.Withdrawn
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Glipizide.Approved, Vet Approved
AicarAicar may increase the hypoglycemic activities of Glipizide.Experimental
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Glipizide.Approved
AlogliptinAlogliptin may increase the hypoglycemic activities of Glipizide.Approved
AlprenololAlprenolol may increase the hypoglycemic activities of Glipizide.Approved, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Glipizide.Approved
AmiodaroneThe metabolism of Glipizide can be decreased when combined with Amiodarone.Approved, Investigational
AOP200704Aop200704 may increase the hypoglycemic activities of Glipizide.Investigational
AprepitantThe serum concentration of Glipizide can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Glipizide can be decreased when used in combination with Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the hypoglycemic activities of Glipizide.Approved
Arsenic trioxideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Asenapine.Approved
AtazanavirThe metabolism of Glipizide can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypoglycemic activities of Glipizide.Approved
AtomoxetineThe metabolism of Glipizide can be decreased when combined with Atomoxetine.Approved
AtorvastatinAtorvastatin may increase the hypoglycemic activities of Glipizide.Approved
BalaglitazoneBalaglitazone may increase the hypoglycemic activities of Glipizide.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
BefunololBefunolol may increase the hypoglycemic activities of Glipizide.Experimental
BendroflumethiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Glipizide.Withdrawn
BetamethasoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the hypoglycemic activities of Glipizide.Approved
BevantololBevantolol may increase the hypoglycemic activities of Glipizide.Approved
BexaroteneThe serum concentration of Glipizide can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateBezafibrate may increase the hypoglycemic activities of Glipizide.Approved
BisoprololBisoprolol may increase the hypoglycemic activities of Glipizide.Approved
BoceprevirThe metabolism of Glipizide can be decreased when combined with Boceprevir.Approved
BopindololBopindolol may increase the hypoglycemic activities of Glipizide.Approved
BortezomibThe metabolism of Glipizide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Glipizide can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Glipizide can be decreased when used in combination with Brexpiprazole.Approved
BucindololBucindolol may increase the hypoglycemic activities of Glipizide.Investigational
BuforminBuformin may increase the hypoglycemic activities of Glipizide.Withdrawn
BufuralolBufuralol may increase the hypoglycemic activities of Glipizide.Experimental, Investigational
BumetanideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Bumetanide.Approved
BupranololBupranolol may increase the hypoglycemic activities of Glipizide.Approved
BuserelinThe therapeutic efficacy of Glipizide can be decreased when used in combination with Buserelin.Approved
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Glipizide.Approved
CapecitabineThe metabolism of Glipizide can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Glipizide can be increased when combined with Carbamazepine.Approved, Investigational
CarbocisteineThe risk or severity of adverse effects can be increased when Glipizide is combined with Carbocisteine.Approved
CaroxazoneCaroxazone may increase the hypoglycemic activities of Glipizide.Withdrawn
CarteololCarteolol may increase the hypoglycemic activities of Glipizide.Approved
CarvedilolCarvedilol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
CastanospermineCastanospermine may increase the hypoglycemic activities of Glipizide.Experimental
CeliprololCeliprolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
CeritinibThe serum concentration of Glipizide can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Glipizide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpropamideChlorpropamide may increase the hypoglycemic activities of Glipizide.Approved
ChlorthalidoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Chlorthalidone.Approved
CholecalciferolThe metabolism of Glipizide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneCiglitazone may increase the hypoglycemic activities of Glipizide.Experimental
CimetidineThe serum concentration of Glipizide can be increased when it is combined with Cimetidine.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Glipizide.Approved, Withdrawn
CiprofibrateCiprofibrate may increase the hypoglycemic activities of Glipizide.Approved
CiprofloxacinCiprofloxacin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
CitalopramCitalopram may increase the hypoglycemic activities of Glipizide.Approved
ClarithromycinThe serum concentration of Glipizide can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Glipizide can be decreased when combined with Clemastine.Approved
ClofibrateClofibrate may increase the hypoglycemic activities of Glipizide.Approved
ClotrimazoleThe metabolism of Glipizide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Clozapine.Approved
CobicistatThe metabolism of Glipizide can be decreased when combined with Cobicistat.Approved
ColesevelamThe serum concentration of Glipizide can be decreased when it is combined with Colesevelam.Approved
ConivaptanThe serum concentration of Glipizide can be increased when it is combined with Conivaptan.Approved, Investigational
CorticotropinThe therapeutic efficacy of Glipizide can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Cortisone acetate.Approved
CrizotinibThe metabolism of Glipizide can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Glipizide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Glipizide can be decreased when it is combined with Dabrafenib.Approved
DanazolThe therapeutic efficacy of Glipizide can be decreased when used in combination with Danazol.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Glipizide.Investigational
DarunavirThe metabolism of Glipizide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Glipizide can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Glipizide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Glipizide can be decreased when combined with Delavirdine.Approved
DeoxyspergualinDeoxyspergualin may increase the hypoglycemic activities of Glipizide.Investigational
dersalazinedersalazine may increase the hypoglycemic activities of Glipizide.Investigational
DesogestrelThe therapeutic efficacy of Glipizide can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Glipizide.Approved
DexamethasoneThe serum concentration of Glipizide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Diazoxide.Approved
DicoumarolGlipizide may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe therapeutic efficacy of Glipizide can be decreased when used in combination with Dienogest.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Glipizide.Approved
DihydroergotamineThe metabolism of Glipizide can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Glipizide.Illicit
DiltiazemThe metabolism of Glipizide can be decreased when combined with Diltiazem.Approved
DisopyramideDisopyramide may increase the hypoglycemic activities of Glipizide.Approved
DoxycyclineThe metabolism of Glipizide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Glipizide can be decreased when combined with Dronedarone.Approved
DrospirenoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Drospirenone.Approved
DulaglutideDulaglutide may increase the hypoglycemic activities of Glipizide.Approved
DuloxetineDuloxetine may increase the hypoglycemic activities of Glipizide.Approved
EfavirenzThe serum concentration of Glipizide can be decreased when it is combined with Efavirenz.Approved, Investigational
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Glipizide.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Glipizide.Approved
EnzalutamideThe serum concentration of Glipizide can be decreased when it is combined with Enzalutamide.Approved
EpinephrineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Epinephrine.Approved, Vet Approved
ErythromycinThe metabolism of Glipizide can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Glipizide.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Glipizide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the hypoglycemic activities of Glipizide.Approved
EstradiolThe therapeutic efficacy of Glipizide can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Glipizide can be decreased when used in combination with Etacrynic acid.Approved
EthanolThe risk or severity of adverse effects can be increased when Glipizide is combined with Ethanol.Approved
Ethinyl EstradiolThe therapeutic efficacy of Glipizide can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethyl biscoumacetateGlipizide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Ethynodiol diacetate.Approved
EtofibrateEtofibrate may increase the hypoglycemic activities of Glipizide.Approved
EtonogestrelThe therapeutic efficacy of Glipizide can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Glipizide.Approved
EtravirineThe serum concentration of Glipizide can be decreased when it is combined with Etravirine.Approved
EverolimusThe therapeutic efficacy of Glipizide can be decreased when used in combination with Everolimus.Approved
ExenatideExenatide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
FenofibrateFenofibrate may increase the hypoglycemic activities of Glipizide.Approved
FleroxacinFleroxacin may increase the hypoglycemic activities of Glipizide.Approved
FloxuridineThe metabolism of Glipizide can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Glipizide can be increased when it is combined with Fluconazole.Approved
FludrocortisoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Fludrocortisone.Approved
FluindioneGlipizide may increase the anticoagulant activities of Fluindione.Investigational
FlumequineFlumequine may increase the hypoglycemic activities of Glipizide.Withdrawn
FluorouracilThe metabolism of Glipizide can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the hypoglycemic activities of Glipizide.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Glipizide.Approved, Illicit
FluvastatinThe metabolism of Glipizide can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Glipizide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Glipizide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Glipizide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Glipizide can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Glipizide.Approved, Vet Approved
FurosemideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Glipizide can be increased when it is combined with Fusidic Acid.Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Glipizide.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GemfibrozilThe metabolism of Glipizide can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlibornurideGlibornuride may increase the hypoglycemic activities of Glipizide.Withdrawn
GliclazideGlipizide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGlimepiride may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneGliquidone may increase the hypoglycemic activities of Glipizide.Approved
GlyburideGlyburide may increase the hypoglycemic activities of Glipizide.Approved
GoserelinThe therapeutic efficacy of Glipizide can be decreased when used in combination with Goserelin.Approved
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Glipizide.Withdrawn
GusperimusGusperimus may increase the hypoglycemic activities of Glipizide.Investigational
HistrelinThe therapeutic efficacy of Glipizide can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Glipizide.Approved
HydrochlorothiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydroflumethiazide.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IdelalisibThe serum concentration of Glipizide can be increased when it is combined with Idelalisib.Approved
IloperidoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Iloperidone.Approved
ImatinibThe metabolism of Glipizide can be decreased when combined with Imatinib.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Glipizide.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Indapamide.Approved
IndenololIndenolol may increase the hypoglycemic activities of Glipizide.Withdrawn
IndinavirThe metabolism of Glipizide can be decreased when combined with Indinavir.Approved
Insulin AspartGlipizide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirGlipizide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Glipizide.Approved
Insulin GlulisineGlipizide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Glipizide.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Glipizide.Approved
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Glipizide.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Glipizide.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Glipizide.Withdrawn
IrbesartanThe metabolism of Glipizide can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Glipizide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Glipizide.Approved
IsradipineThe metabolism of Glipizide can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Glipizide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Glipizide can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Glipizide can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the hypoglycemic activities of Glipizide.Approved
LanreotideGlipizide may increase the hypoglycemic activities of Lanreotide.Approved
LeflunomideThe metabolism of Glipizide can be decreased when combined with Leflunomide.Approved, Investigational
LeuprolideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the hypoglycemic activities of Glipizide.Approved
LevofloxacinLevofloxacin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Glipizide.Approved
LevonorgestrelThe therapeutic efficacy of Glipizide can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LinagliptinLinagliptin may increase the hypoglycemic activities of Glipizide.Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Glipizide.Approved, Nutraceutical
LiraglutideLiraglutide may increase the hypoglycemic activities of Glipizide.Approved
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Glipizide.Approved
LopinavirThe metabolism of Glipizide can be decreased when combined with Lopinavir.Approved
LosartanThe metabolism of Glipizide can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Glipizide can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Glipizide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Glipizide can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Lurasidone.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Glipizide.Withdrawn
MecaserminGlipizide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MesalazineMesalazine may increase the hypoglycemic activities of Glipizide.Approved
MestranolThe therapeutic efficacy of Glipizide can be decreased when used in combination with Mestranol.Approved
MetforminMetformin may increase the hypoglycemic activities of Glipizide.Approved
MethotrimeprazineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Glipizide.Investigational
MethylprednisoloneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Glipizide.Approved
MetipranololMetipranolol may increase the hypoglycemic activities of Glipizide.Approved
MetolazoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Metolazone.Approved
MetoprololMetoprolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
MetreleptinMetreleptin may increase the hypoglycemic activities of Glipizide.Approved
MiconazoleMiconazole may increase the hypoglycemic activities of Glipizide.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Glipizide can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolMiglitol may increase the hypoglycemic activities of Glipizide.Approved
MiglustatMiglustat may increase the hypoglycemic activities of Glipizide.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Glipizide.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Glipizide.Approved
MitiglinideMitiglinide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
MitotaneThe serum concentration of Glipizide can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypoglycemic activities of Glipizide.Approved
ModafinilThe serum concentration of Glipizide can be decreased when it is combined with Modafinil.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
NadololNadolol may increase the hypoglycemic activities of Glipizide.Approved
NafcillinThe serum concentration of Glipizide can be decreased when it is combined with Nafcillin.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Glipizide.Approved
NateglinideNateglinide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
NCX 4016NCX 4016 may increase the hypoglycemic activities of Glipizide.Investigational
NefazodoneThe metabolism of Glipizide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Glipizide can be decreased when combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Glipizide.Investigational
NetupitantThe serum concentration of Glipizide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Glipizide can be increased when combined with Nevirapine.Approved
NiacinThe therapeutic efficacy of Glipizide can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Glipizide.Withdrawn
NicardipineThe metabolism of Glipizide can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Glipizide can be decreased when combined with Nilotinib.Approved, Investigational
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Glipizide.Investigational
NorethisteroneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Glipizide.Approved
NorgestimateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Norgestimate.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Glipizide.Withdrawn
OctreotideOctreotide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
OfloxacinOfloxacin may increase the hypoglycemic activities of Glipizide.Approved
OlanzapineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Glipizide can be decreased when combined with Olaparib.Approved
OlsalazineOlsalazine may increase the hypoglycemic activities of Glipizide.Approved
OmeprazoleThe metabolism of Glipizide can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Glipizide can be increased when it is combined with Osimertinib.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Glipizide.Approved, Investigational
OxprenololOxprenolol may increase the hypoglycemic activities of Glipizide.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Glipizide.Approved, Illicit
PalbociclibThe serum concentration of Glipizide can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Paliperidone.Approved
PargylinePargyline may increase the hypoglycemic activities of Glipizide.Approved
ParoxetineParoxetine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
PasireotideGlipizide may increase the hypoglycemic activities of Pasireotide.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Glipizide.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Glipizide.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Glipizide.Approved
PenbutololPenbutolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
PentamidinePentamidine may increase the hypoglycemic activities of Glipizide.Approved
PentobarbitalThe metabolism of Glipizide can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Glipizide.Approved
PhenforminPhenformin may increase the hypoglycemic activities of Glipizide.Approved, Withdrawn
PhenindioneGlipizide may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the hypoglycemic activities of Glipizide.Withdrawn
PhenobarbitalThe metabolism of Glipizide can be increased when combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Glipizide.Withdrawn
PhenprocoumonGlipizide may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe metabolism of Glipizide can be increased when combined with Phenytoin.Approved, Vet Approved
PindololPindolol may increase the hypoglycemic activities of Glipizide.Approved
PioglitazonePioglitazone may increase the hypoglycemic activities of Glipizide.Approved, Investigational
PiperazineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Pipotiazine.Approved
PirlindolePirlindole may increase the hypoglycemic activities of Glipizide.Approved
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Glipizide.Withdrawn
PolythiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Polythiazide.Approved
PosaconazolePosaconazole may increase the hypoglycemic activities of Glipizide.Approved, Investigational, Vet Approved
PractololPractolol may increase the hypoglycemic activities of Glipizide.Approved
PramlintidePramlintide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
PrednisoloneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Glipizide can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe protein binding of Glipizide can be decreased when combined with Probenecid.Approved
ProgesteroneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Progesterone.Approved, Vet Approved
PropranololPropranolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Glipizide.Investigational
PyrimethamineThe metabolism of Glipizide can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Quinethazone.Approved
QuinineQuinine may increase the hypoglycemic activities of Glipizide.Approved
RanitidineThe serum concentration of Glipizide can be increased when it is combined with Ranitidine.Approved
RanolazineThe metabolism of Glipizide can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Glipizide.Approved
RepaglinideRepaglinide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
RifabutinThe metabolism of Glipizide can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Glipizide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Glipizide can be increased when combined with Rifapentine.Approved
RisperidoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe metabolism of Glipizide can be decreased when combined with Ritonavir.Approved, Investigational
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Glipizide.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Glipizide.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Glipizide.Withdrawn
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Glipizide.Approved, Vet Approved
SaquinavirThe metabolism of Glipizide can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Glipizide.Approved
SecobarbitalThe metabolism of Glipizide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypoglycemic activities of Glipizide.Approved, Investigational, Vet Approved
SertralineSertraline may increase the hypoglycemic activities of Glipizide.Approved
SildenafilThe metabolism of Glipizide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Glipizide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Glipizide can be increased when it is combined with Simeprevir.Approved
SirolimusThe therapeutic efficacy of Glipizide can be decreased when used in combination with Sirolimus.Approved, Investigational
SitagliptinSitagliptin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
SorafenibThe metabolism of Glipizide can be decreased when combined with Sorafenib.Approved, Investigational
SotalolSotalol may increase the hypoglycemic activities of Glipizide.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Glipizide.Approved
St. John's WortThe serum concentration of Glipizide can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololStanozolol may increase the hypoglycemic activities of Glipizide.Approved, Vet Approved
StiripentolThe serum concentration of Glipizide can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Glipizide can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the hypoglycemic activities of Glipizide.Approved
SulfisoxazoleThe metabolism of Glipizide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideSulodexide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
SunitinibGlipizide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of Glipizide can be decreased when used in combination with Tacrolimus.Approved, Investigational
TelaprevirThe metabolism of Glipizide can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Glipizide can be decreased when combined with Telithromycin.Approved
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Glipizide.Withdrawn
TemsirolimusThe therapeutic efficacy of Glipizide can be decreased when used in combination with Temsirolimus.Approved
TestosteroneTestosterone may increase the hypoglycemic activities of Glipizide.Approved, Investigational
ThiazolidinedioneThiazolidinedione may increase the hypoglycemic activities of Glipizide.Investigational
TicagrelorThe metabolism of Glipizide can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Glipizide can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the hypoglycemic activities of Glipizide.Approved
TipranavirThe therapeutic efficacy of Glipizide can be decreased when used in combination with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Glipizide can be decreased when it is combined with Tocilizumab.Approved
TolazamideTolazamide may increase the hypoglycemic activities of Glipizide.Approved
TolbutamideThe metabolism of Glipizide can be decreased when combined with Tolbutamide.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Glipizide.Approved
TorasemideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Torasemide.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Glipizide.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Glipizide.Approved
TriamcinoloneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TrimethoprimThe metabolism of Glipizide can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Glipizide can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TroglitazoneTroglitazone may increase the hypoglycemic activities of Glipizide.Withdrawn
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Glipizide.Approved, Withdrawn
Valproic AcidThe metabolism of Glipizide can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Glipizide can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe metabolism of Glipizide can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Glipizide can be decreased when combined with Verapamil.Approved
VildagliptinVildagliptin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
VogliboseVoglibose may increase the hypoglycemic activities of Glipizide.Approved, Investigational
VoriconazoleThe serum concentration of Glipizide can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe therapeutic efficacy of Glipizide can be decreased when used in combination with Vorinostat.Approved, Investigational
WarfarinGlipizide may increase the anticoagulant activities of Warfarin.Approved
ZafirlukastThe metabolism of Glipizide can be decreased when combined with Zafirlukast.Approved, Investigational
ZimelidineZimelidine may increase the hypoglycemic activities of Glipizide.Withdrawn
ZiprasidoneThe metabolism of Glipizide can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid sugar and sugary food.
  • Take 30-60 minutes before breakfast.
References
Synthesis Reference

Suresh Kumar Gidwani, Purushottam Singnurkar, Prashant Kumar Tewari, “Sustained release pharmaceutical composition containing glipizide and method for producing same.” U.S. Patent US6270797, issued February, 2000.

US6270797
General ReferencesNot Available
External Links
ATC CodesA10BB07
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (48.8 KB)
MSDSDownload (73.6 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingBasic ScienceType 2 Diabetes Mellitus (T2D)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentType 2 Diabetes Mellitus (T2D)1
2CompletedTreatmentImpaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus (T2D)1
2CompletedTreatmentType 2 Diabetes Mellitus (T2D)1
3CompletedTreatmentAtherosclerosis / Cardiovascular Diseases / Non-Insulin-Dependent Diabetes Mellitus1
3CompletedTreatmentChronic Renal Insufficiency / Type 2 Diabetes Mellitus (T2D)1
3CompletedTreatmentDiabetes Mellitus (DM)1
3CompletedTreatmentEnd-Stage Kidney Disease / Type 2 Diabetes Mellitus (T2D)1
3CompletedTreatmentRenal Insufficiency,Chronic / Type 2 Diabetes Mellitus (T2D)1
3CompletedTreatmentType 2 Diabetes Mellitus (T2D)7
4CompletedTreatmentCoronary Artery Disease / Type 2 Diabetes Mellitus (T2D)1
4CompletedTreatmentType 2 Diabetes Mellitus (T2D)3
4Unknown StatusBasic ScienceType 2 Diabetes Mellitus (T2D)1
4Unknown StatusTreatmentSevere Hyperglycemia - Blood Glucose Level >300mg/dl / Type 2 Diabetes Mellitus (T2D)1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus (T2D)3
Not AvailableCompletedHealth Services ResearchGenotyping / Pharmacokinetics1
Not AvailableRecruitingTreatmentChronic Kidney Disease (CKD) / Type 2 Diabetes Mellitus (T2D)1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral5 mg/1
Tablet, film coatedOral
Tablet, film coated, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral2.5 mg/1
Tablet, film coated, extended releaseOral5 mg/1
Tablet, extended releaseOral10 mg/1
Tablet, extended releaseOral2.5 mg/1
Tablet, extended releaseOral5 mg/1
Prices
Unit descriptionCostUnit
Glipizide powder36.11USD g
Glucotrol XL 10 mg 24 Hour tablet1.53USD tablet
Glucotrol xl 10 mg tablet1.37USD tablet
Metaglip 5-500 mg tablet1.33USD tablet
Metaglip 2.5-500 mg tablet1.32USD tablet
Metaglip 2.5-250 mg tablet1.2USD tablet
Glucotrol 10 mg tablet1.19USD tablet
Glucotrol XL 2.5 mg 24 Hour tablet0.99USD tablet
Glucotrol XL 5 mg 24 Hour tablet0.99USD tablet
GlipiZIDE XL 10 mg 24 Hour tablet0.84USD tablet
Glucotrol 5 mg tablet0.69USD tablet
Glucotrol xl 2.5 mg tablet0.69USD tablet
Glucotrol xl 5 mg tablet0.69USD tablet
Glipizide 10 mg tablet0.67USD tablet
GlipiZIDE XL 2.5 mg 24 Hour tablet0.63USD tablet
GlipiZIDE XL 5 mg 24 Hour tablet0.5USD tablet
Glipizide 5 mg tablet0.36USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2024502 No1997-11-112010-08-31Canada
US5024843 No1992-09-052009-09-05Us
US5591454 No1994-01-072014-01-07Us
USRE44459 No1999-03-262019-03-26Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point200-203U.S. Patent 3,669,966.
water solubility37.2 mg/LNot Available
logP1.91HANSCH,C ET AL. (1995)
pKa5.9PANTEN,U ET AL. (1989)
Predicted Properties
PropertyValueSource
Water Solubility0.0164 mg/mLALOGPS
logP1.83ALOGPS
logP1.43ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)4.32ChemAxon
pKa (Strongest Basic)0.059ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area130.15 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity115.62 m3·mol-1ChemAxon
Polarizability47.64 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9262
Blood Brain Barrier+0.5599
Caco-2 permeable-0.7025
P-glycoprotein substrateSubstrate0.5326
P-glycoprotein inhibitor INon-inhibitor0.7469
P-glycoprotein inhibitor IINon-inhibitor0.9302
Renal organic cation transporterNon-inhibitor0.8322
CYP450 2C9 substrateSubstrate0.5731
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.719
CYP450 1A2 substrateNon-inhibitor0.9501
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.7745
CarcinogenicityNon-carcinogens0.826
BiodegradationNot ready biodegradable0.9703
Rat acute toxicity2.1662 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9118
hERG inhibition (predictor II)Non-inhibitor0.8539
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Benzenesulfonamide
  • Benzenesulfonyl group
  • Sulfonylurea
  • Pyrazine
  • Organic sulfonic acid or derivatives
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Organosulfonic acid or derivatives
  • Carboximidic acid
  • Carboximidic acid derivative
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organopnictogen compound
  • Organic oxygen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sulfonylurea receptor activity
Specific Function:
Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.
Gene Name:
ABCC8
Uniprot ID:
Q09428
Molecular Weight:
176990.36 Da
References
  1. Gribble FM, Ashcroft FM: Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism. 2000 Oct;49(10 Suppl 2):3-6. [PubMed:11078468 ]
  2. Harrower A: Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. Metabolism. 2000 Oct;49(10 Suppl 2):7-11. [PubMed:11078469 ]
  3. Lawrence CL, Proks P, Rodrigo GC, Jones P, Hayabuchi Y, Standen NB, Ashcroft FM: Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia. 2001 Aug;44(8):1019-25. [PubMed:11484080 ]
  4. Reimann F, Ashcroft FM, Gribble FM: Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9. [PubMed:11574406 ]
  5. Proks P, Reimann F, Green N, Gribble F, Ashcroft F: Sulfonylurea stimulation of insulin secretion. Diabetes. 2002 Dec;51 Suppl 3:S368-76. [PubMed:12475777 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation...
Gene Name:
PPARG
Uniprot ID:
P37231
Molecular Weight:
57619.58 Da
References
  1. Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, Albrecht H, Schwede T, Meyer UA, Rucker C: Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol Pharmacol. 2007 Feb;71(2):398-406. Epub 2006 Nov 2. [PubMed:17082235 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 27, 2017 04:00